Vedanta Biosciences, Inc.

Charting a New World of Medicines

Vedanta is a late-stage clinical biotechnology company developing first-in-class oral therapies for the treatment of serious gastrointestinal diseases. Its pipeline includes product candidates VE303, currently enrolling patients into a Phase 3 registrational trial in recurrent C. difficile infection, and VE202, currently enrolling patients into a Phase 2 trial in IBD.

Program Indication Funding MOA Preclinical cmc Phase 1 Phase 2 Phase 3 Rights
VE303 C. difficile
Preclinical Phase complete
cmc Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
VE202 Inflammatory Bowel Disease
Preclinical Phase complete
cmc Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
VE707 Gram-negative Infections
Preclinical Phase complete
cmc Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Third-Party Led Trials VE818 EED (Led by Gates Foundation)
Preclinical Phase complete
cmc Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started

MOA: Mechanism of Action; CMC; Chemistry, Manufacturing and Controls; EED: Environmental Enteric Dysfunction; FPI: First Patient Dosed; TLD: Top Line Data

Colonization
resistance

Immuno -
regulation

Our Partners

We aim to collaborate with partners to advance bacterial consortia therapeutics either through direct licensing of our products or our intellectual property.

We also collaborate with clinical and academic institutions to learn from human interventional studies and to further our mechanistic understanding of bacterial consortia therapeutics.

View Partnerships